<DOC>
	<DOCNO>NCT02210182</DOCNO>
	<brief_summary>The purpose study investigate Hepatic Uptake , Pharmacokinetics , Safety Tolerance New Oral Pentamidine Formulation Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation</brief_summary>
	<brief_title>A Phase I Clinical Study New Oral Pentamidine Formulation Hepatocellular Carcinoma</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , sequential-group administration new oral pentamidine formulation investigate hepatic uptake , pharmacokinetics , safety tolerance subject hepatocellular carcinoma undergoes thermal ablation procedure</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>1 . Male female subject 2 . 18 year age old 3 . Radiologically establish diagnosis hepatocellular carcinoma ( HCC ) tumor diameter ≤ 5 cm 4 . Suitable scheduled undergo thermal ablation treatment 5 . Have Barcelona score 0 A 6 . Have Child Pugh score A B 7 . Legally mentally able give inform consent participate study 8 . Signature date Informed Consent Form ( ICF ) indicate subject inform relevant aspect trial prior enrolment 9 . Willingness ability comply schedule visit trial procedure 1 . Presence uncontrolled diabetes , define glycated hemoglobin ( Hb1Ac ) ≥ 8.0 2 . History clinically significant hypoglycaemia , fast blood glucose &lt; 3 mmol/L within 3 month prior signature ICF 3 . Presence clinically significant renal impairment , define creatinine clearance &lt; 60 mL/min 4 . Systolic Blood Pressure &lt; 100 mm Hg ( deem clinically significant treat physician ) 5 . Current recent ( &lt; 2 year ) history pancreatitis 6. International Normalised Ratio ( INR ) &gt; 1.5 presence severe coagulation disorder ( vg limit prothrombin activity &lt; 40 % platelet count &lt; 40,000 / mm3 ) 7 . Presence known vascular invasion , bile duct invasion extrahepatic metastasis 8 . Presence portal venous thrombosis 9 . Concomitant therapy investigational agent participation another clinical trial within 3 month signature ICF 10 . Previous use pentamidine treatment discontinuation le 6 month prior signature ICF 11 . Any following condition : Ongoing clinically significant cardiac dysrhythmias atrial fibrillation ; QTc interval &gt; 450 msec male &gt; 470 msec female uncontrolled intercurrent cardiac illness , e.g . unstable angina ; severe coronary disease , ventricular arrhythmia , bradycardia &lt; 50 bpm ( unless cause betablocker ) ; history additional risk factor torsades de pointes ( e.g. , heart failure family history Long QTC Syndrome ) 12 . Presence clinically significant hypokalemia hypomagnesemia 13 . Concurrent use nephrotoxic drug 14 . Concurrent use cardiotoxic drug 15 . Concurrent use drug may associate pancreatitis 16 . History allergy hypersensitivity pentamidine 17 . Pregnancy breastfeed . All female subject childbearing potential must negative urine pregnancy test prior first dose study medication . 18 . Acute chronic severe medical psychiatric condition , laboratory abnormality would impart , judgement investigator , excess risk associate trial participation study drug administration , judgement investigator , would make subject inappropriate entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Oral Pentamidine</keyword>
	<keyword>Endo-exonuclease</keyword>
</DOC>